Best Sleep Medication for Short-Term Insomnia in Healthy Adults
For short-term insomnia in a healthy adult, use zolpidem 10 mg or eszopiclone 2-3 mg as first-line pharmacologic options, as these non-benzodiazepine hypnotics have the strongest evidence for both sleep onset and maintenance with acceptable short-term safety profiles.
Primary Medication Recommendations
Based on the 2017 American Academy of Sleep Medicine (AASM) guidelines 111, the following medications receive weak recommendations for short-term use:
For Both Sleep Onset AND Maintenance Problems:
- Eszopiclone (2-3 mg): Addresses both falling asleep and staying asleep 11
- Zolpidem (10 mg): Effective for both components of insomnia 11
- Temazepam (15 mg): Benzodiazepine option for both types 1
For Sleep Onset Only:
- Zaleplon (10 mg): Ultra-short acting, ideal for difficulty falling asleep 1
- Triazolam (0.25 mg): Short half-life benzodiazepine 1
- Ramelteon (8 mg): Melatonin receptor agonist, lower abuse potential 1
For Sleep Maintenance Only:
- Suvorexant (10-20 mg): Orexin receptor antagonist for staying asleep 1
- Doxepin (3-6 mg): Low-dose sedating antidepressant 1
Critical Safety Considerations
The 2016 American College of Physicians evidence review 2 found that while eszopiclone, zolpidem, and suvorexant improve sleep outcomes, observational studies suggest hypnotic use is associated with increased risks of:
- Dementia
- Fractures
- Major injury
- Cognitive and behavioral changes including driving impairment
The FDA specifically advises dose reduction in women and older adults 2. These serious harms must be weighed against the modest absolute effect sizes seen in trials.
Medications to AVOID
The AASM guidelines explicitly recommend AGAINST the following 11:
- Trazodone (50 mg)
- Diphenhydramine (antihistamine)
- Melatonin (over-the-counter formulations)
- Tiagabine
- L-tryptophan
- Valerian
Despite some recent expert consensus suggesting diphenhydramine for acute insomnia 3, the higher-quality AASM guidelines take precedence and recommend against it due to insufficient evidence and anticholinergic side effects 11.
Duration of Treatment
All recommendations are for SHORT-TERM use (≤4 weeks) 4. The European guidelines 4 specify:
- Benzodiazepines and Z-drugs: ≤4 weeks
- Orexin receptor antagonists: up to 3 months
- Longer-term use may be considered in select cases with careful risk-benefit assessment
Clinical Algorithm
Step 1: Identify the specific insomnia pattern:
- Sleep onset only → Zaleplon, triazolam, or ramelteon
- Sleep maintenance only → Suvorexant or doxepin
- Both → Zolpidem or eszopiclone (preferred for comprehensive coverage)
Step 2: Consider patient-specific factors:
- Women and older adults: Use lower FDA-recommended doses due to increased adverse effects 2
- Concern about dependence: Choose ramelteon or suvorexant (non-controlled substances)
- Middle-of-night awakening: Zaleplon can be used for this specific indication 5
Step 3: Plan for discontinuation from the start:
- Set expectation for 4-week maximum duration
- Taper benzodiazepines and Z-drugs by 10-25% weekly when discontinuing 6
- Consider transition to CBT-I (cognitive behavioral therapy for insomnia), which should be first-line treatment when available 47
Important Caveats
All pharmacologic recommendations carry only WEAK strength in the AASM guidelines 1, reflecting:
- Small absolute effect sizes
- Short trial durations
- Industry funding bias
- Limited long-term safety data
The evidence consistently shows that cognitive behavioral therapy for insomnia (CBT-I) should be first-line treatment when available 47, with medications reserved for when CBT-I is ineffective or unavailable 1.
Common pitfall: Prescribing for longer than 4 weeks without reassessment. Short-term insomnia often resolves, and chronic use increases risks of dependence, tolerance, and the serious harms noted above 2.